上海招聘

1. Responsibilities of Process

工艺职责

 1.1 To support world class manufacturing with robust, costeffective and manufacturable designs for both product and raw material. Lead technical elements of closed loop corrective action and problem solving within SASS plant and at suppliers. Solve manufacturing problems of related products in production. Initiate and implement productivity improvement projects.

 以世界领先的标准支持生产活动，以期达到低成本、稳健生产和可持续生产产品和原料的目标；对供应商及本厂区的问题进行彻底的技术整改和解决；解决相关产品生产过程中出现的技术问题，提高劳动生产率

  1.1.1 Solve all kinds of problems in routine commercial production. Find the root cause from the technical process aspect. Find ways to solve the problems with other related departments. Implement the measures in routine production and follow up the results. 解决日常生产过程中产品出现的各种问题；从工艺的角度寻找问题产生的根本原因；和其它相关部门一起找到解决问题的方法；并在实际生产中实施，同时跟踪问题解决的效果

 1.1.2 Improve the manufacturing process continuously in order to improve the productivity. Improve the process of related commercial products including weighing, granulation, final mixing, tablet compression, coating, packaging, etc. Improve the productivity, save the labor hours, reduce the circle time and decrease the strength of the labor.

持续改进生产工艺，提高生产效率；对现有的相关产品通过对称量、制粒、总混、压片、包衣和包装等各个工序的生产工艺进行改进；提高生产效率，节约劳动工时，减少生产周期，降低劳动强度

2. Responsibilities of Validation

验证职责

 2.1 Generate the qualification protocol and circulate for approval including (but not limited to) process & product, system validation, cleaning validation, method validation and equipment performance qualification, etc.

建立认证的方案并流转批准，包括（但不限于）产品和工艺验证、系统验证、清洁验证、方法验证、设备运行验证等

  2.1.1 Conduct qualification trials.  指导认证试验

  2.1.2 Investigate and document any out of tolerance conditions.   调查异常情况

  2.1.3 Accumulate, compile and evaluate all test results.   积累，评估测试结果

  2.1.4 Prepare the qualification report and circulate for approval.  准备验证报告和流转签字

 2.2 Compliance

合规

  2.2.1 Ensure validation related activities and documentation are in compliance with regulatory, quality and safety guidelines. 确保验证相关活动和文件符合质量和安全指南的要求

 2.3 For any process & system that have been validated after three years, assessment study will be carried out according to the Validation Guideline issued by BMS Headquarters. Confirmation validation will be performed if determined to be necessary after document review.

  对于公司已有的任何产品工艺和系统，且已做过验证后三年，根据BMS总部发布的验证指南要求进行评估研究；在审阅后，如有必要将进行确认验证

3. New Product Development Responsibilities    新产品开发职责

 3.1 Coordinate Worldwide Technical for any technical initiatives and implementation of the initiatives in the plant and technical transfer for specific new product/project.

确保全球制药总部发起的特定的新产品/新项目在本工厂的实施和技术转移

Experiences Desired

相关工作经验要求

1. 5 years or above relevant working experience in a Multi-national pharmaceutical industry

5年以上跨国医药企业相关工作背景

2. Experience in product/process validation, site service and new product development.

在产品工艺验证、生产现场服务和新产品开发方面有丰富的知识与经验

Educational/Knowledge Desired (including professional qualifications & language proficiency)

必要的学历和专业资格，含语言能力

1. Bachelor degree or above, major in Pharmaceutical or related subject

本科学历或以上，主修制药或相关专业

2. Have an excellent ability to listen, speak, read and write in both English and Chinese

具有良好的中英文听说读写能力

Skills & Ability Desired

必要的技能和能力

1. Ability to use MS Office

具备使用办公室软件的能力

2. Ability of proactive in problem finding and solving problems, good team work and ability to communicate

具备发现问题、解决问题，良好的团队合作精神及沟通的能力

3. Ability of positive, proactive, always look for opportunities and challenge

具备积极主动、总能寻找机会和挑战的能力

百时美施贵宝是一家以“研发并提供创新药物，帮助患者战胜严重疾病”为使命的全球性生物制药公司。公司拥有约25000名员工。2016年，百时美施贵宝全球研发投入达近50 亿美元，占全年产品净销售额的28%。

2007年，百时美施贵宝作出了一个重大的战略调整，即向新一代生物制药企业转型。如今，百时美施贵宝将进一步向多元化的特药生物制药企业转型，朝更创新、专业和以患者为中心的方向发展，引领行业新变革。百时美施贵宝将专注于创新药物的研究，以解决肿瘤、免疫肿瘤及肝炎等疾病领域的迫切需求。

在百时美施贵宝，我们为了患者共同努力。作为生物制药行业的引领者，我们致力于为患者提供革新性药物，以治疗最严峻且最具挑战性的疾病，并努力使我们的药物在全球内具有可及性。在为与严重疾病作斗争的患者带来希望的共同信念下，百时美施贵宝以领先的科学发展和创新的产品组合投身于中国市场。

公司于1982年进入中国，于同年成立的中美上海施贵宝制药有限公司是在中国改革开放以后成立的***家中美合资制药企业，目前由百时美施贵宝（中国）投资有限公司、上海医药集团股份有限公司以及国药集团资产管理中心共同投资。

如今，中国已是百时美施贵宝公司全球重要的研发、生产、营销和创新中心之一。百时美施贵宝致力于满足中国未被满足的迫切的重大疾病需求，重点关注于病毒性肝炎和免疫肿瘤两大疾病领域，引领行业发展，开展多元合作，加速提供创新的生物制药产品，以帮助中国患者战胜严重疾病。